Politicians, experts, and patient representatives call for the UK government to reverse the rate of antidepressant prescribing

2023/12/05 by James Davies, John Read, Danny Kruger +28 · 1 voice · 2 citations
Economics, Econometrics and Finance · Medicine · Psychology · #Health Systems, Economic Evaluations, Quality of Life #Mental Health Treatment and Access #Treatment of Major Depression

paper · pdf · doi:10.1136/bmj.p2730

openalex publication_date 2023/12/05 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/17

Abstract

We, a group of medical professionals, researchers, patient representatives, and politicians, call for the UK government to commit to a reversal

Citations

• Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
• The costs incurred by the NHS in England due to the unnecessary prescribing of dependency-forming medications

Cited by

• ‘We’re all doing different things’ — exploring primary care practitioners' perspectives of managing distress: a qualitative study
• Examining the Long-Term Impacts of Psychotropic Drugs and Considerations for People Discontinuing Treatment

Discussions

• To be clear, this new Parliamentary group calling for reduced rates of antidepressant prescription are entirely concerned with cutting NHS spending as an alternative to funding our healthcare services [bsky, 0 points, 0 comments]

Related

• Influences on antidepressant prescribing trends in the UK: 1995–2011
• The trouble with antidepressants: why the evidence overplays benefits and underplays risks—an essay by John B Warren
• Impact of the COVID-19 pandemic on antidepressant prescribing with a focus on people with learning disability and autism: an interrupted time series analysis in England using OpenSAFELY-TPP
• Barriers and facilitators to antidepressant deprescribing – A qualitative interview study with general practitioners in Germany
• Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines